Studies in the 5T33 murine myeloma model already showed the efficacy of lenalidomide in combination with blockade of other immune checkpoints (e.g. CTLA-4, LAG-3, TIM-3, and combinations thereof [44]). The gene discussed is CTLA4; the disease is plasma cell myeloma.